Understanding the Latest Therapeutic Advances in Multiple Myeloma

Join us for a live CME/CE-certified event to hear from experts on the latest data and therapeutic options for patients with myeloma.


Introduction and Overview of Myeloma

Case Discussion 1: When Should Systemic Myeloma Treatment Be Initiated?

  • Accurate diagnosis of MM and assessment of risk
  • Techniques and biomarkers for diagnosis

Case Discussion 2: Individualized Approaches to Frontline Treatment

  • Understanding how patient and disease factors guide therapy decisions
  • Optimal induction, consolidation, and maintenance approaches for individual patients
  • Supportive care strategies for patients undergoing treatment for MM

Case Discussion 3: Therapeutic Strategies for Relapsed or Refractory Myeloma

  • Planning optimal agent combinations for therapy
  • New and future options for relapsed/refractory disease

Conclusions and Audience Question and Answer Session


Date / Time
Event Details


Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD

Professor and Chair 
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Melissa Alsina, MD

Head, Multiple Myeloma BMT Program
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Ajai Chari, MD

Associate Professor of Medicine
Mount Sinai School of Medicine
Director of Clinical Research
Multiple Myeloma Program
New York, New York

raymond comenzo, MD

Director, John Conant Davis Myeloma and Amyloid Program
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Sarah Holstein, MD

Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Amrita Krishnan, MD, FACP

Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope
Duarte, California

Heather Landau, MD

Assistant Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Suzanne Lentzsch, MD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Elisabet E. Manasanch, MD

Assistant Professor 
Division of Cancer Medicine
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this activity is to improve participants’ competence to provide optimal care for patients with multiple myeloma.

Target Audience 
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives 

  • Integrate timely systemic treatment for appropriate patients based on current multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Identify ongoing trials of investigational approaches in the treatment of multiple myeloma to aid referral of patients for study participation


Physician Continuing Medical Education

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
1.0 contact hour may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program has been assigned ACPE Universal Activity #0797-9999-18-222-L01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit. 

Type of Activity: Application

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.